ReviewDermatologie (Heidelberg, Germany)2022
[Melanoma microenvironment-impact of modern therapies].
Review in Dermatologie (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA considerable proportion of patients with advanced melanoma succumb to metastatic disease despite the initial success of modern therapies.
objectivesAn overview of the melanoma tumor microenvironment with special focus on approved therapies and new innovative strategies is given.
methodsCurrent clinical trials and scientific insights concerning the impact of the tumor microenvironment on progression and therapy of advanced melanoma are reviewed and discussed.
resultsThe tumor microenvironment with its manifold components and interactions plays a major role in the treatment of malignant melanoma.
conclusionInnovative new strategies that target an immunosuppressive microenvironment may improve the therapeutic efficacy of current treatment of advanced melanoma.
Indexed as
Identifiers
36394589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.